ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1489 • 2014 ACR/ARHP Annual Meeting

    Influences of Disease Activity at the Initiation of Iguratimod, a Small Molecule Antirheumatic Drug, on Efficacy of Iguratimod in Patients with Rheumatoid Arthritis –a Multicenter Registry Study-

    Yuji Hirano1, Toshihisa Kojima2, Yasuhide Kanayama3, Shinya Hirabara1, Nobunori Takahashi2, Atsushi Kaneko4 and Naoki Ishiguro2, 1Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, 2Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 3Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, 4Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan

    Background/Purpose: Iguratimod (IGU), known as T-614, is a small-molecule antirheumatic drug developed in Japan and used in Japanese clinical practice since June in 2012. IGU…
  • Abstract Number: 1487 • 2014 ACR/ARHP Annual Meeting

    A Phase 1 Dose-Ranging Repeated-Dose Trial of Parenteral Staphylococcal Protein A (PRTX-100) in Patients with Active Rheumatoid Arthritis on Methotrexate or Leflunamide Therapy

    Craig Wiesenhutter1,2, Rakesh Patel3, John Lavery4, Nighat Tahir5,6, Lydie Hazan7, Alan Kivitz8, Elizabeth Bretton9 and Jeffrey Kaine10, 1University of Washington School of Medicine, Seattle, WA, 2Coeur d’Alene Arthritis Clinic, Coeur d’Alene, ID, 3PMG Research of Salisbury, Salisbury, NC, 4Allen Arthritis and Allergy, Allen, TX, 5Community Hospital of Anderson and Madison County, Inc., Anderson, IN, 6Community Rheumatology of Anderson, Anderson, IN, 7Axis Clinical Trials, Los Angeles, CA, 8Altoona Center for Clinical Research, Duncansville, PA, 9Albuquerque Clinical Trials, Albuquerque, NM, 10Sarasota Arthritis Center, Sarasota, FL

    Background/Purpose Staphylococcal protein A (SpA) binds with high affinity to the Fc region of human immunoglobulin G and also to the Fab framework region of…
  • Abstract Number: 1492 • 2014 ACR/ARHP Annual Meeting

    Safety and Tolerability of NNC0114­0006, an Anti-IL-21 Monoclonal Antibody, at Multiple s.c. Dose Levels in Patients with Rheumatoid Arthritis

    Frank Wagner1, Birte Skrumsager2 and Sergey Fitilev3, 1Charité Research Org GmbH, Berlin, Germany, 2Novo Nordisk A/S, Søborg, Denmark, 3Department of Clinical Pharmacology, Municipal Clinic #2, Moscow, Russia

    Background/Purpose A phase 1, randomised, double-blind, placebo-controlled, dose-escalation trial was conducted to assess the safety and tolerability of the anti-IL-21-antibody NNC0114-0006, in patients with active…
  • Abstract Number: 1472 • 2014 ACR/ARHP Annual Meeting

    Synovial Fluid from Rheumatoid Arthritis Patients Modulates the Immunophenotype and Viability of Monocytes

    Maria Sole Chimenti, Alberto Bergamini, Eleonora Baffari, Eleonora Ballanti, Alessia Musto, Paola Conigliaro and Roberto Perricone, Rheumatology, allergology and clinical immunology, Department of "Medicina dei Sistemi", University of Rome "Tor Vergata", Rome, Italy

    Background/Purpose Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by infiltration of the synovium by inflammatory cells that destroys the cartilage and the…
  • Abstract Number: 1471 • 2014 ACR/ARHP Annual Meeting

    TNFα Influences the Status of B and T Cells By Acting on BCR and TCR Pathways Via RasGRP1 and RasGRP3 Proteins

    Marie-Laure Golinski1, Martine Hiron2, Céline Derambure2, Clément Guillou1, Manuel Fréret2, Olivier Boyer3, Olivier Vittecoq4 and Thierry Lequerré5, 1Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, 2Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, Rouen, France, 3Immunology, INSERM U905, University of Rouen, Rouen, France, 4Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 51 Rue De Germont, Chu De Rouen, Rouen, France

    Background/Purpose Rheumatoid arthritis (RA) is the most common inflammatory arthritis. B and T cells play a key role in the RA pathophysiology. RasGRP is a…
  • Abstract Number: 1470 • 2014 ACR/ARHP Annual Meeting

    Malondialdehyde-Acetaldehyde Adducts (MAA) and Anti-Malondialdehyde-Acetaldehyde Antibody in Rheumatoid Arthritis

    Geoffrey Thiele1, Michael J. Duryee2, Daniel Anderson3, Lynell W. Klassen4, Stephen Mohring5, Kathleen Young6, Dathe Benissan-Messan7, Harlan Sayles3, Jeremy Sokolove8, William H. Robinson9, James O' Dell3, Anthony Nicholas10 and Ted R. Mikuls3, 1Int Med/Sec of Rheum/Immun, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 2Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 4Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 5Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 6Int Med/Sec of Rheum/Immun, University of Nebraska Medical Center, Omaha, NE, 7University of Nebraska Medical Center, Omaha, NE, 8VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, 9VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 10Neurology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose:   Products of oxidative stress, MAA adducts are highly immunogenic and have been associated with tolerance loss.  To examine their potential role in disease-related…
  • Abstract Number: 1469 • 2014 ACR/ARHP Annual Meeting

    Methotrexate Treatment Reduces Serum IL-6 Level By Decreasing a CD14brightCD16+ Intermediate Non-Classical Subset of Monocytes in RA Patients

    Masako Tsukamoto1, Keiko Yoshimoto2, Noriyuki Seta3, Katsuya Suzuki2 and Tsutomu Takeuchi2, 1Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Department of Internal Medicine, Keio university, Tokyo, Japan

    Background/Purpose It is well known that circulating monocytes are the source of inflammatory cytokines, such as IL-6 and TNFα and newly divided into three subsets…
  • Abstract Number: 1467 • 2014 ACR/ARHP Annual Meeting

    Do G-CSF and Neutrophils Contribute to the Pathophysiology of Rheumatoid Arthritis?

    Gabrielle Goldberg1, Simon Chatfield2,3, Jane Murphy1, Ee Shan Pang1, Yunshun Chen4, Gordon Smyth4, Milica Ng5, Michael Wilson5, Clare O'Neill3, Samantha Busfield5, Arna Andrews5 and Ian P. Wicks3,6,7, 1Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, 2Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, 3Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, 4Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, 5Research, CSL Limited, Melbourne, Australia, 6Inflammation, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, 7Medical Biology, The University of Melbourne, Melbourne, Australia

    Background/Purpose Rheumatoid arthritis (RA) is characterised by a persistent, but poorly understood interplay between innate and adaptive immunity. Neutrophils are the predominant cell type in…
  • Abstract Number: 1468 • 2014 ACR/ARHP Annual Meeting

    Mechanism of Effectiveness of IL-6 Blockade for Reduction of SAA Production and Amyloid a Deposition in AA Amyloidosis Patients with RA

    Kazuyuki Yoshizaki, Osaka University, Osaka, Japan

    Background/Purpose AA amyloidosis is a serious complication of chronic inflammatory and infectious diseases resulting from the deposition of amyloid A protein. Serum amyloid A (SAA),…
  • Abstract Number: 1466 • 2014 ACR/ARHP Annual Meeting

    Patients with Active Rheumatoid Arthritis Display an Expanded Population of GM-CSF Expressing Peripheral B Cells

    Sofia Adamidi, Anastasia Makris, Christos Koutsianas, Christina Tsalapaki, Emilia Hadziyannis and Dimitrios Vassilopoulos, 2nd Department of Medicine and Laboratory of Clinical Immunology-Rheumatology, Hippokration General Hospital, University of Athens Medical School, Athens, Greece

    Background/Purpose GM-CSF has been implicated in rheumatoid arthritis (RA) pathogenesis and is being investigated as a novel therapeutic target. B cells secreting GM-CSF have been…
  • Abstract Number: 1465 • 2014 ACR/ARHP Annual Meeting

    Follicular Helper T Cells Control Autoimmunity through IL-21/IL-21 Receptor Interaction in RA Patients

    Shikha Singla1, Minzi Chen2, Jerry Pounds Jr.2, Omar Khan2, Jerald M. Zakem2, Kismet Collins2, Tamika Webb-Detiege2, William E. Davis2, Robert Quinet2 and Xin Zhang3, 1Rheumatology, Ochner Medical Center, New Orleans, LA, 2Rheumatology, Ochsner Medical Center, New Orleans, LA, 3Institute of Translational Research, Ochsner Medical Center, New Orleans, LA

    Background/Purpose Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovium, causing progressive joint destruction and reduction in quality of life…
  • Abstract Number: 1464 • 2014 ACR/ARHP Annual Meeting

    Numbers of Circulating CD4 Positive CD28null T Cells Are Increased in Patients with Rheumatoid Arthritis and Are Associated with Rheumatoid Factor Positivity but Not Subclinical Cardiovascular Disease

    Sarah Skeoch1, John Waterton2, Yvonne Alexander3 and Ian N. Bruce4, 1Arthritis Research UK Centre for Epidemiology and NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 2Bioimaging Institute, University of Manchester, Manchester, United Kingdom, 3Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, 4Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom

    Background/Purpose CD4+ T cells which lack CD28 co-expression (CD28null cells) account for less than 2.5% of CD4+ T cells in healthy individuals. These cells are…
  • Abstract Number: 1463 • 2014 ACR/ARHP Annual Meeting

    Dickkopf-1 Perpetuated Synovial Fibroblast Activation and Synovial Angiogenesis in Rheumatoid Arthritis

    Li Zheng1, Fanlei Hu2, Yingni Li1, Lianjie Shi2, Xiaoxu Ma1, Xuewu Zhang3 and Zhanguo Li4, 1Peking University People's Hospital, Beijing, China, 2Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 311 South Street, XiZhiMen , We, Peking University People's Hospital, Beijing, China, 4Rheum/Immunology, Peking University People's Hospital, Beijing, China

    Background/Purpose . Dkk-1, a master regulator of joint remodeling, is elevated and leads to bone resorption in patients with RA. This study aimed to investigate…
  • Abstract Number: 1482 • 2014 ACR/ARHP Annual Meeting

    Response of Patient Reported Symptoms of Stiffness and Pain during the Day from Adding Low-Dose Delayed-Release (DR) Prednisone to Stable DMARD Therapy over 12 Weeks in Patients with Moderate Rheumatoid Arthritis (RA)

    Rieke Alten1, Amy Y. Grahn2, Patricia Rice3, Robert Holt4 and Frank Buttgereit5, 1Charité University Medicine, Berlin, Germany, 2Horizon Pharma, Inc., Deerfield, IL, 3Premier Research, Naperville, IL, 4College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL, 5Charité University Hospital, Berlin, Germany

     Background/Purpose: RA patients experience stiffness which impacts their daily lives.  Although this patient reported symptom was dropped from the RA classification criteria there is growing…
  • Abstract Number: 1481 • 2014 ACR/ARHP Annual Meeting

    Phase 1 and Phase 2 Data Confirm That GLPG0634, a Selective JAK1 Inhibitor, Has a Low Potential for Drug-Drug Interactions

    Namour Florence1, Desrivot Julie1, Annegret Van der Aa2, Chantal Tasset3 and Gerben van 't Klooster2, 1Galapagos, Romainville, France, 2Galapagos NV, Mechelen, Belgium, 3Generaal de Wittelaan L11 A3, Galapagos NV, Mechelen, Belgium

    Background/Purpose: GLPG0634 is an orally-available, selective Janus kinase 1 (JAK1) inhibitor. Selective inhibition of JAK1 may combine improved safety and clinical efficacy profiles with a rapid onset of…
  • « Previous Page
  • 1
  • …
  • 1951
  • 1952
  • 1953
  • 1954
  • 1955
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology